{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '86', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'If the investigator recommends continuation of study intervention beyond disease', 'progression, the participant or his/her legally acceptable representative will be asked to sign', 'consent.', 'Specifics about the study and the study population are to be included in the study informed', 'consent form.', 'Informed consent will adhere to IRB/IEC requirements, applicable laws and regulations, and', 'Sponsor requirements.', '8.1.2', 'Inclusion/Exclusion Criteria', 'All inclusion and exclusion criteria will be reviewed by the investigator who is a qualified', 'physician to ensure that the participant qualifies for the study.', '8.1.3', 'Participant Identification Card', 'All participants will be given a participant identification card identifying them as participants', 'in a research study. The card will contain study site contact information (including direct', 'telephone numbers) to be used in the event of an emergency. The investigator or qualified', 'designee will provide the participant with a participant identification card immediately after', 'the participant provides documented informed consent. At the time of intervention', 'allocation/randomization, site personnel will add the treatment/randomization number to the', 'participant identification card.', 'The participant identification card also contains contact information for the emergency', 'unblinding call center so that a healthcare provider can obtain information about study', 'intervention in emergency situations where the investigator is not available.', '8.1.4', 'Medical History', '8.1.4.1', 'General Medical History', 'A medical history will be obtained by the investigator or qualified designee.', 'Medical history will include all active conditions, drug allergies, significant medical', 'procedures, and any condition diagnosed within the previous 10 years that are considered to', 'be clinically important by the investigator. Any cancer, other than the cancer under study,', 'will be recorded as medical history, even if diagnosed greater than 10 years before', 'enrollment. Details regarding the cancer under study will be recorded separately and not', 'listed as medical history. The medical history will also include an assessment of smoking', 'history.', '8.1.4.2', 'Oncologic Disease Details', 'The investigator or qualified designee will obtain historic and current details of the', \"participant's cancer under study. This information will include, but is not limited to, date of\", 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '87', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'diagnosis, stage, histology, locations of primary lesions, and location of metastases, if', 'applicable.', '8.1.5', 'Prior and Concomitant Medications Review', '8.1.5.1', 'Prior Medications', 'The investigator or qualified designee will review prior medication use, including any', 'protocol-specified washout requirement, and record prior medication taken by the participant', 'within 30 days before the first dose of study intervention. Treatment for the disease for which', 'the participant has enrolled in the study will be recorded separately and not listed as a prior', 'medication.', '8.1.5.2', 'Prior Oncologic Treatment', 'The investigator or qualified designee will review and record all treatments for the cancer', 'under study, including systemic and local treatment, vaccinations, radiation, and surgeries.', 'Additional information collected on these treatments will include, but is not limited to,', 'reason for discontinuation, best response, and date of progression after each treatment as', 'applicable.', '8.1.5.3', 'Concomitant Medications', 'NOTE: As of Amendment 007-06, the Second-course Treatment Phase has been', 'removed from the study. This section has been updated accordingly.', 'The investigator or qualified designee will record medication, if any, taken by the participant', 'during the study. Concomitant medications will be recorded for 30 days after the last dose of', 'study intervention (or 90 days if used to treat an SAE).', \"Any new anticancer therapy started after the participant's discontinuation from the treatment\", 'period will be recorded separately. Additional information collected on this treatment will', 'include, but is not limited to, best response and date of progression.', '8.1.6', 'Assignment of Screening Number', 'All consented participants will be given a unique screening number that will be used to', 'identify the participant for all procedures that occur prior to randomization. Each participant', 'will be assigned only 1 screening number. Screening numbers must not be re-used for', 'different participants.', 'Any participant who is screened multiple times will retain the original screening number', 'assigned at the initial screening visit. Specific details on the screening/rescreening visit', 'requirements are provided in Section 8.11.1.', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}